Emergent BioSolutions is a contract manufacturer that produces both the Johnson & Johnson and AstraZeneca coronavirus vaccines.
According to The New York Times, the vaccine spoilage was due to human error, when workers at the plant mixed up the ingredients of the Johnson & Johnson and AstraZeneca vaccines.
The Maryland-based company fell to as low as $79.40 a share Thursday. The stock is down 3.22% in the last month.
Emergent BioSolutions was expected to produce tens of millions of doses of the Johnson & Johnson vaccine in the coming months. The mishap will delay production and shipment schedules for weeks, according to the Times.
Johnson & Johnson fell as much as 1.3% Thursday before paring back losses.